NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company\'s lead product candidate, will be presented in...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]al-meeting-2021-301281575.html